SCHEMBL21873056

SCHEMBL21873056

Cc1nc(-c2cnc(NC(C)C)[nH]c2=O)ccc1Cc1cn(C(=O)OC(C)(C)C)c2ncccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 12/20 0.44
▸ PDGFRA P16234 6/20 0.44
▸ PDGFRB P09619 2/20 0.44
▸ KDR P35968 2/20 0.43
▸ FLT3 P36888 4/20 0.35
▸ ELANE P08246 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CES2 O00748 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ CCNB2 O95067 2/20 0.31
▸ CDK1 P06493 2/20 0.31
▸ CCNB1 P14635 2/20 0.31
▸ CCNB3 Q8WWL7 2/20 0.31
▸ TYK2 P29597 1/20 0.31
▸ PDPK1 O15530 1/20 0.31
▸ PRKCB P05771 1/20 0.31
▸ LYN P07948 1/20 0.31
▸ CCNA2 P20248 1/20 0.31
▸ CDK2 P24941 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28337392 0.90 CSF1R (0.45) CSF1RPDGFRAPDGFRBKDRFLT3
SCHEMBL21872988 0.86 CSF1R (0.42) CSF1RPDGFRAPDGFRBKDRFLT3
SCHEMBL21873140 0.78 GPR84 (0.46) CSF1RPDGFRAPDGFRBKDRFLT3
SCHEMBL21906312 0.76 CSF1R (0.43) CSF1RPDGFRAPDGFRBKDRFLT3
SCHEMBL22978451 0.76 L3MBTL1 (0.41) ELANEL3MBTL1
SCHEMBL21873001 0.75 CSF1R (0.44) CSF1RPDGFRAPDGFRBKDRFLT3
SCHEMBL22978450 0.73 ELANE (0.39) ELANEL3MBTL1ALDH1A1
SCHEMBL4505573 0.71 L3MBTL1 (0.39) ELANEL3MBTL1
SCHEMBL21873148 0.70 CSF1R (0.44) CSF1RPDGFRAPDGFRBKDRFLT3
SCHEMBL21873010 0.70 CSF1R (0.46) CSF1RPDGFRAPDGFRBKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRA 229/4885PDGFRB 149/4885
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRA 229/4885PDGFRB 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback